Podcasts about spinraza

In the week since Donald Trump took office, he's caused quite the stir with healthcare-centered moves that include ordering the Department of Health and Human Services to stop communications, hiring and travel and announcing that he would withdraw the U.S. from the World Health Organization. Wednesday, the U.S. Senate Finance Committee convenes to vote on the controversial nomination of Robert F. Kennedy, Jr. for health secretary—a vote that Jefferies analysts said they expect to be “close.” Biogen continues to grab headlines this month, as the latest chapter in the Sage saga saw the smaller biotech rejecting its neuro partner's unsolicited buyout offer. Meanwhile, Biogen laid off an undisclosed number of employees from its research unit, just as a higher dose of its Ionis-partnered spinal muscular atrophy therapy Spinraza was accepted for review by both the FDA and EMA. Elsewhere, the weight loss space continues to click on all cylinders, with Versant Ventures debuting its newest obesity biotech Helicore Biopharma on Tuesday with $65 million in series A funds, and two obesity-focused companies, Aardvark Therapeutics and Metsera, seeking entry to the public markets. These up-and-comers will have to compete against the likes of Eli Lilly and Novo Nordisk, the latter of which reported data last week showing that its next-gen obesity drug amycretin could elicit up to 22% weight-loss. And Veru announced that its enobosarm could significantly improve the quality of weight loss in seniors also taking Novo's Wegovy. Another busy therapeutic space is Duchenne muscular dystrophy, where analysts predict a lot of action in the next couple of years, with a number of data readouts and regulatory submissions. And finally, Annalee Armstrong caught up at JPM with Novavax CEO John Jacobs, who said the vaccine maker is at a pivot point.

* We should all be so lucky as to have vision like that of the mantis shrimp: Not only do its eyes possess four times as many color receptors as a human's, it can see UV, visible and polarized light as well. * The rise in global temperatures has led to flowers emitting less scent. * Lightning hasn't brought down an airplane since 1963, thanks to engineering that allows a bolt's electric charge to run through and out of the aircraft. * Spinraza, a drug prescribed for spinal muscular dystrophy, has a list price of 0,000. * By 2018, more...Article Link

Join Sheila and Sara this week as they cover Osteogenesis Imperfecta and Neuromuscular Diseases (with a primary focus on DMD). We also touch on Becker MD, congenital MD, facioscapulohumeral muscular dystrophy, Myotonic dystrophy, Emery-Dreifuss MD and SMA. Please note, the content for SMA is from Campbell, but we recognize the quickly evolving presentation of that disease with the introduction of Spinraza and other medications. Please be mindful of this during the episode. Enjoy. Affiliate Codes: ------------------------------------------ Medbridge Affiliate website: https://www.medbridgeeducation.com/pushing-pediatrics Medbridge Affiliate Code: PUSHINGPEDS ----------------------------------------- Resources: Palisano, R. J., Orlin, M. N., & Schreiber, R. (2023). Campbell's physical therapy for children. Elsevier.

Welcome to the NeurologyLive® Mind Moments® podcast. Tune in to hear leaders in neurology sound off on topics that impact your clinical practice. In this episode, Thomas Crawford, MD, a pediatric neurologist at Johns Hopkins Medicine, spoke on the recently published 5-year analysis of the NURTURE study (NCT02386553), a long-term trial assessing the efficacy and safety of nusinersen (Spinraza; Biogen) in presymptomatic infants with spinal muscular atrophy (SMA). Crawford discussed the significance of the positive findings, the shift in conversations around treatment optimization in SMA, and how subgroup data may factor into the design of future trials. Looking for more Neuromuscular Disorders discussion? Check out the NeurologyLive® neuromuscular clinical focus page. Episode Breakdown: 1:20 – Benefits seen with nusinersen in NURTURE  4:10 – Changes in goals for treating SMA 6:05 – Complexities with getting infants therapy days after diagnosis 9:40 – Neurology News Minute 12:30 – Subgroup findings from NURTURE 15:20 – Ways to improve treatment optimization in SMA This episode is brought to you by Medical World News, a streaming channel from MJH Life Sciences®. Check out new content and shows every day, only at medicalworldnews.com. The stories featured in this week's Neurology News Minute, which will give you quick updates on the following developments in neurology, are further detailed here: World Health Organization Adds Several MS Treatments to List of Essential Medicines Ceribell's Status Epilepticus Software Receives FDA Clearance With CMS NTAP Coverage Included FDA Accepts New Drug Application for Long-Acting Form of Glatiramer Acetate Essential Tremor Agent Ulixacaltamide Continues to Show Positive Results in Essential1 Study Thanks for listening to the NeurologyLive® Mind Moments® podcast. To support the show, be sure to rate, review, and subscribe wherever you listen to podcasts. For more neurology news and expert-driven content, visit neurologylive.com.

Kyle Filkins and Kris Napper were both born with SMA, spinal muscular atrophy. Meeting as kids at The Muscular Dystrophy Association summer camp, they have developed a friendship and a documentary. After beginning the use of the drug Evrysdi, their rare genetic disease stopped progressing, and the oral form of this medication allowed them to avoid spinal injections. Now in their thirties, Kris and Kyle are advocating for the community of those with SMA, working on their documentary, and looking forward to more adventures.  Kris explains, "Just shortly before Evrysdi was released and made available, there was another drug called Spinraza that was the first treatment ever for our disability. It was a spinal injection, which poses some complications as far as it's a procedure with some risk. It can be painful, and there's the risk of hitting nerves and causing damage. It's not the most fun thing to go through, but it was beneficial. So I was doing that." "So for young children, just being diagnosed can be life-changing because you can stop that progression before it really hits. For us, we've already had significant progression. Still, hopefully, this will stop it where it is, and we'll be able to continue our lives for the foreseeable future, a lot better and longer than originally anticipated." Kyle elaborates, "Before I was on any type of therapy, I would go to bed one day able to do something, and I'd wake up the day after not being able to do that. And it would never come back. And it's pretty great to be able to go to bed and sleep securely knowing that what I did today I can, for the most part, probably do tomorrow. It's definitely life-changing. That's for sure." "There's been a lot of people interested in this story. Kind of piggybacking here on what Napper said, at the outset, it was really kind of just a budget film and like, "Oh, maybe they'll do cool activities and make jokes and stuff." But then with the advent of this therapy and specifically Evrysdi, that's really changed the outlook of the scope of the film, and for the better, as Napper said."  @KKtheFilm #SMA #SpinalMuscularAtrophy #MuscularDystrophy #RareDisease #Evrysdi  KrisandKyletheFilm.com SnappyClothing.com Evrysdi.com Listen to the podcast here

Kyle Filkins and Kris Napper were both born with SMA, spinal muscular atrophy. Meeting as kids at The Muscular Dystrophy Association summer camp, they have developed a friendship and a documentary. After beginning the use of the drug Evrysdi, their rare genetic disease stopped progressing, and the oral form of this medication allowed them to avoid spinal injections. Now in their thirties, Kris and Kyle are advocating for the community of those with SMA, working on their documentary, and looking forward to more adventures.  Kris explains, "Just shortly before Evrysdi was released and made available, there was another drug called Spinraza that was the first treatment ever for our disability. It was a spinal injection, which poses some complications as far as it's a procedure with some risk. It can be painful, and there's the risk of hitting nerves and causing damage. It's not the most fun thing to go through, but it was beneficial. So I was doing that." "So for young children, just being diagnosed can be life-changing because you can stop that progression before it really hits. For us, we've already had significant progression. Still, hopefully, this will stop it where it is, and we'll be able to continue our lives for the foreseeable future, a lot better and longer than originally anticipated." Kyle elaborates, "Before I was on any type of therapy, I would go to bed one day able to do something, and I'd wake up the day after not being able to do that. And it would never come back. And it's pretty great to be able to go to bed and sleep securely knowing that what I did today I can, for the most part, probably do tomorrow. It's definitely life-changing. That's for sure." "There's been a lot of people interested in this story. Kind of piggybacking here on what Napper said, at the outset, it was really kind of just a budget film and like, "Oh, maybe they'll do cool activities and make jokes and stuff." But then with the advent of this therapy and specifically Evrysdi, that's really changed the outlook of the scope of the film, and for the better, as Napper said."  @KKtheFilm #SMA #SpinalMuscularAtrophy #MuscularDystrophy #RareDisease #Evrysdi  KrisandKyletheFilm.com SnappyClothing.com Evrysdi.com Download the transcript here

Today we are talking to Aofie Brennan, president and CEO of Synlogic. Aoife was trained as a doctor at Trinity College Dublin following which she moved to the US. After completing her postdoctoral research at Beth Israel Aofie joined TolerX focused on developing autoimmune therapies for type I diabetes. Following which Aoife spent 6 years at Biogen ultimately becoming head of Rare Disease Innovation, she was involved in the development of Spinraza, Alprolix and Eloctate. Aoife moved from Biogen to Synlogic where she initially took the CMO role ultimately being elected as CEO and President of the company. She has led Synlogic since 2018. Beyond Synlogic Aoife is on the BoD of Cerevance and Fibrogen having also served on the board of RA Pharma through its acquisition by UCB.We discuss Aoife's career trajectory, her experiences at Biogen and decision to join Synlogic. Navigating the failure of their lead program in 2020 as a public company and building a deep pipeline today. In addition we discuss diversity and inclusion in our biotech industry today and ways this could be more impactful.Please join me in welcoming Aoife. 

Dr. Wendy Chung's childhood fascination with puzzles and mysteries gives her an edge when it comes to solving the mysteries of genetic diseases. In conversation with Host Catherine Price, Dr. Chung outlines her innovative work with The Human Genome project, her role in identifying the genes that cause spinal muscular atrophy and the collaborative efforts that went into developing life-sustaining treatments. Dr. Chung also discusses the GUARDIAN Program – which uses the newborn heel prick test to screen for a wide variety of genetic diseases, thereby providing equitable access to diagnosis and life-saving care to all infants. The views shared on this podcast solely reflect the expertise and experience of our guests. For more information visit nyp.org/Advances

An Auckland mum has moved her family across the ditch to Sydney so she can access a life-saving drug. Fiona Tolich has been advocating for Pharmac to fund Spinraza since she developed spinal muscular atrophy 12 years ago. Pharmac has announced it's funding the medicine for under 19s from this year, but Tolich isn't young enough. Fiona says she couldn't take the chance on waiting for funding for her age group. LISTEN ABOVESee omnystudio.com/listener for privacy information.

As some of you may know, our host Kira Dineen also co-produces the “Patient Empowerment Program” by n-Lorem. The podcast launched earlier this year and focuses solely on the needs of people with nano-rare diseases. These are people who have a unique pathogenic variant (aka mutation) that affects 30 or less people in the world, sometimes just one person. The host of the show is Dr. Stan Crooke, who will be a familiar voice to you if you are a long time listener of DNA Today. He was on Episode 141 where I picked his brain about nano-rare diseases. He is a scientist, physician, entrepreneur and the father of antisense technology. Dr. Crooke is responsible for more than 40 drugs in development including the famous Spinraza to treat people with spinal muscular atrophy. So this week we are sharing an episode of the podcast where Dr. Crooke interviews Dr. Sessions Cole about the diagnosed odyssey for people with rare diseases. Dr. Sessions Cole shares his career being a neonatal pulmonologist and his involvement in the undiagnosed diseases network (UDN). Dr. Cole estimates that it can take up to 12 years to get a diagnosis for a patient with a rare genetic condition and that there could be as many as 30 million of these patients in the U.S. who are undiagnosed. The UDN is working to elevate the awareness of the diagnostic odyssey these patients undertake and diagnose up to one third of patients who are referred to the UDN. Dr. Cole is part of n-Lorem's access to treat committee (ATTC), the committee that evaluates and recommends patients to n-Lorem. In this episode, Dr. Cole discusses the robust processes involved in the evaluation of each application to n-Lorem and the hope and value that n-Lorem is providing to nano-rare patients today.To hear other episodes of the n-Lorem “Patient Empowerment Program'', subscribe on Spotify, Apple Podcast, their website, YouTube, or wherever you stream your podcasts. The host is Dr. Stan Crooke, videographer is Jon Magnuson of Mightyone Productions, producers are Jon Magnuson and Kira Dineen. Stay updated with n-Lorem on Twitter, Instagram, Facebook, Linked In, YouTube and their website, nlorem.org. Questions/inquiries can be sent to podcast@nlorem.org. Stay tuned for the next new episode of DNA Today on October 28th! New episodes are released every Fridays. In the meantime, you can binge over 200 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. Our outreach Intern is Sanya Tinaikar. Our Social Media Intern is Kajal Patel. And our Graphic Designer Ashlyn Enokian.See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNAToday.com. Questions/inquiries can be sent to info@DNAtoday.com.

Synopsis: Stanley Crooke is Founder and CEO of n-Lorem Foundation, a nonprofit with the goal of discovering, developing and providing experimental ASO treatments to nano-rare patients for free for life. He joins us for a discussion about the business model behind rare diseases and how n-Lorem is looking to industrialize and scale the treatment of this unique population. Stanley talks about the challenges behind developing and bringing a new modality to the clinic, the company's collaboration with the FDA, and how n-Lorem seeks to be sustainable and scalable over time. Biography: Dr. Crooke is the founder, chairman and chief executive officer of n-Lorem, a nonprofit foundation focused on providing treatments for patients with nano-rare disease (1 to 30 patients worldwide), which he initiated in January 2020. Prior to n- Lorem, Dr. Crooke founded and was Chairman and Chief Executive Officer and Lead Scientist of Ionis Pharmaceuticals. During his tenure at Ionis, he led the scientific development of a new platform for drug discovery, antisense technology and the creation of one of the largest and more advanced development pipelines in the biotechnology industry, and commercialized several antisense drugs including, Spinraza, Tegsedi and others. Early in Dr. Crooke's career, he led the creation of the first broad anticancer program in the industry at Bristol-Myers, bringing numerous anticancer drugs to the market in the first five years of his career. He then assumed responsibility for worldwide R&D (president) at SmithKline Beckman (now GSK). During his tenure at SKB, Dr. Crooke led the restructuring of R&D and the development of several drugs that were commercialized. Dr. Crooke has also contemporaneously led a successful academic career becoming a full professor at Baylor College of Medicine and the University of Pennsylvania Medical School where he trained a number of PhD students and won several teaching awards. Dr. Crooke has been an active scientist throughout his career as well. Dr. Crooke has received a number of awards, most recently, Prix Galein Roy Vagellos Pro Bono Humanum Award, the American Chemical Society's E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances, the Lifetime Achievement Award presented by the Oligonucleotide Therapeutics Society, the Scrip Lifetime Achievement Award and the 2019 Massry Prize. Dr. Crooke received his M.D. and Ph.D. degrees and house staff training at Baylor College of Medicine and has been an active scientist throughout his career. In 2021, Dr. Crooke has been named Distinguished Alumnus of both Baylor College of Medicine's Graduate and Medical schools and named one of the 20 of the most influential biopharma R&D executives by Endpoints News. He has published nearly 600 scientific publications, edited more than 20 books, has numerous patents, and led the development of more than 23 drugs that have been commercialized.

A drug which could radically change the lives of people who have spinal muscular atrophy is finally set to be funded in New Zealand. Spinraza is one of two new treatments to get the green light from Pharmac  It's the first drug for SMA to be fully funded here - and is priceless for families like Rachel Shaw's in Hawke's Bay. Her 11-year-old and 12-year-old have Spinal Muscular Atrophy, and her 7 year old Chloe carries the gene. See omnystudio.com/listener for privacy information.

Two new medicines are set to be funded by Pharmac, potentially affecting tens of thousands of patients. A proposal released this morning would fund Spinraza, a treatment for spinal muscular atrophy, that currently costs up to 390-thousand dollars a year. The second proposal would fund adrenaline auto-injector pens, such as EpiPens, for those with life-threatening allergies. Health Minister Andrew Little spoke to Guyon Espiner.

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

See omnystudio.com/listener for privacy information.

Dr. Aoife Brennan is an experienced physician scientist and drug developer responsible for the successful clinical development and registration of multiple transformative medicines. Aoife has served as Synlogic's president and chief executive officer since May 2018. She joined Synlogic in September 2016 as chief medical officer. Prior to Synlogic, Aoife spent six years at Biogen, most recently as vice president and head of the Rare Disease Innovation Unit, developing programs from pre-clinical to commercial. She has led programs across multiple therapeutic areas including the successful late phase development & registration of SPINRAZA® (nusinersen) for spinal muscular atrophy and ALPROLIX® and ELOCTATE® for Hemophilia B and Hemophilia A, respectively. Aoife serves as a member of the Board of Directors of Cerevance and Fibrogen, Inc, and previously served on the Board of Directors of Ra Pharmaceuticals until it's acquisition by UCB. Earlier in her career, Aoife led clinical development at Tolerx, a start-up biotech company focusing on immunotherapy for Type 1 diabetes. Aoife holds a medical degree from Trinity College in Dublin, Ireland and has completed post-graduate training in internal medicine, endocrinology and metabolism. She has completed post-doctoral training in clinical research and metabolism at the Beth Israel Deaconess Medical Center in Boston and is a graduate of the Harvard Medical School Scholars in Clinical Science Program.

Kathie M. Bishop, Ph.D. is our Senior Vice President, Chief Scientific Officer and Head of Rare Disease. Dr. Bishop has more than 20 years of experience in leading translational research and drug development, with a focus on novel therapeutics for the treatment of neurological and rare diseases. Dr. Bishop joined Acadia from LocanaBio, where she served as Chief Scientific Officer (CSO) and was responsible for research and development for RNA-targeted gene therapies for neurodegenerative and ocular diseases. Prior to LocanaBio, Dr. Bishop was CSO at Otonomy – where she led preclinical and clinical development of a pipeline of neurotology programs – and CSO of Tioga Pharmaceuticals. Prior to that, she served in various product development management roles at Ionis Pharmaceuticals including Vice President, Clinical Development where she led translation and development of multiple programs in the neurology franchise including the development and clinical trials for SPINRAZA® (nusinersen), the first approved treatment for patients with spinal muscular atrophy and winner of the 2017 Prix Galien Award for Biotechnology. Dr. Bishop also served in research and development leadership roles at Ceregene, a company focused on the development of AAV-based gene therapy products for the treatment of neurodegenerative disorders. She conducted post-doctoral work at the Salk Institute for Biological Studies in La Jolla and obtained her Ph.D. from the University of Alberta.Rett Syndrome: https://www.rettsyndrome.org/about-rett-syndrome/Acadia Pharmaceuticals: https://www.acadia-pharm.com/National Institutes of Health: https://www.nih.gov/National Organization for Rare Diseases: https://rarediseases.org/about/Spinraza: https://www.spinraza.com/Host: Kira DorrianProduced by the Northshore Schools Foundation, a Top-Rated “Great Nonprofits” award-recipient, “Guidestar” Gold Participant, and Best of a “Best of Northshore” nonprofit. We are on a Summer schedule. Join us on the third Monday of July, August and September for new episodes!Thank you, supporters! DonateInterested in sponsoring the Skills 4 Life Podcast? Contact us: podcast@nsdfoundation.orgFollow us on:InstagramFacebookSkills 4 Life FacebookTwitterLinked In

Pharmac is being forced to address health inequities that it perpetuates, to open up and be more transparent, and to actually communicate and speak to people with rare diseases when deciding what medicines to buy for them. For people like our next guest, it’s too little too late. Brent Walker has spinal muscular atrophy and has been wheelchair bound since he was three. He says access to the drug Spinraza would change his life, but he can’t wait any longer… he’s moving to Australia. See omnystudio.com/listener for privacy information.

We are thrilled to share a brand new podcast that Kira Dineen co-produces, the n-Lorem “Patient Empowerment Program”. The podcast just launched so we wanted to share the pilot episode with you! This podcast focuses solely, exclusively, on the needs of nano-rare patients. These are patients that have a unique pathogenic variant (mutation) that affects only them or less than 30 people worldwide. The host of the show is Dr. Stan Crooke, who will be a familiar voice to you if you are a long time listener of DNA Today. He was on Episode 141 where we picked his brain about nano-rare patients. He is a scientist, a physician, an entrepreneur and the father of antisense technology. Dr. Crooke is responsible for more than 40 drugs in development including the famous Spinraza to treat people with spinal muscular atrophy. In this pilot episode, the host, Dr. Stan Crooke, is joined by actor and patient advocate Luke Rosen and pediatric geneticist Dr. Wendy Chung. This episode takes you on a journey to diagnosis and what it is like to live with a nano-rare disease.Luke Rosen is the board chair, KIF1A.org, vice president of patient engagement and government affairs at Ovid Therapeutics and father to Susannah. You may have seen him in Law & Order, Orange Is The New Black, Rescue Me, and Numb3rs. To learn more about KIF1A and the organization Luke and his wife, Sally, founded visit kif1a.org. You can follow Luke on Twitter @lukebrosen. Wendy Chung, M.D., Ph.D. is the Kennedy family professor of pediatrics in medicine, chief of the division of clinical genetics, department of pediatrics at Columbia University Medical Center, medical director of Columbia Genetic Counseling Graduate program and director of the clinical cancer genetics program at Columbia. Check out all the great work from Dr. Wendy Chung and her lab at Columbia by visiting wchunglab.com.The host of the show is Dr. Stanley Crooke, a scientist, a physician, an entrepreneur and the father of antisense technology. Dr. Crooke is responsible for driving the development of antisense or ASO technology, an RNA-targeted technology responsible for the commercialization of three best- and first-in class medicines and more than 40 drugs in development. In 2020, Stan formed n-Lorem to use this powerful technology to develop personalized ASO medicines for nano-rare patients (1 to 30 patients worldwide) for free, for life. On This Episode We Discuss:Susannah's journey to a diagnosisKif1A – and what a pathogenic variant (mutation) in this gene meansLiving with a nano-rare diseaseSusannah's courage and joyFinding a treatment for SusannahTo hear other episodes of the n-Lorem “Patient Empowerment Program”, subscribe on Spotify, Apple Podcast, their website, YouTube, or wherever you stream your podcasts. The host is Dr. Stan Crooke, videographer is Jon Magnuson of Mightyone Productions, producers are Jon Magnuson and Kira Dineen. Stay updated with n-Lorem on Twitter, Instagram, Facebook, Linked In, YouTube and their website, nlorem.org. Questions/inquiries can be sent to podcast@nlorem.org. Stay tuned for the next new episode of DNA Today on June 3rd! New episodes are released on Fridays. In the meantime, you can binge over 185 other episodes on Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Today”. Episodes since 2021 are also recorded with video which you can watch on our YouTube channel. DNA Today is hosted and produced by Kira Dineen. Our social media lead is Corinne Merlino. Our video lead is Amanda Andreoli. See what else we are up to on Twitter, Instagram, Facebook, YouTube and our website, DNApodcast.com. Questions/inquiries can be sent to info@DNApodcast.com. PerkinElmer Genomics is a global leader in genetic testing focusing on rare diseases, inherited disorders, newborn screening, and hereditary cancer. Testing services support the full continuum of care from preconception and prenatal to neonatal, pediatric, and adult. Testing options include sequencing for targeted genes, multiple genes, the whole exome or genome, and copy number variations. Using a simple saliva or blood sample, PerkinElmer Genomics answers complex genetic questions that can proactively inform patient care and end the diagnostic odyssey for families. Learn more at PerkinElmerGenomics.com. (SPONSORED)HemoShear Therapeutics is a clinical stage company developing new treatments for patients with rare metabolic disorders. By partnering with fellow biopharma companies, HemoShear is accelerating their drug discovery and development programs in metabolic disorders, and also liver diseases and gout. HemoShear is currently conducting a clinical trial for a new therapy for propionic and methylmalonic Acidemia. Learn more about these conditions and the clinical trial in an upcoming episode of DNA Today! You can also visit hemoshear.com. (SPONSORED)

In 2020 China's pharmaceutical market passed an important milestone, a Deloitte report cited that China was expected to grow its pharmaceutical market volume by 2020 to $220 billion (USD) becoming the second largest market behind the US. The commercial potential is huge, so what do we know about the orphan drug (OD) potential in China? Fisentzos Stylianou discusses China's healthcare system, key challenges for OD manufacturers, Spinraza's commercialisation journey in China, and incentives available to OD manufacturers in China. Reference: https://www2.deloitte.com/cn/en/pages/life-sciences-and-healthcare/solutions/life-sciences.html Presenter: Aparna Krishnan, Partner – Global Operations Contributor: Fisentzos Stylianou, Analyst Producer: Operations team

“Let's talk about patients. That's where we have to always begin. This is about patients. I was tremendously impressed with how much the patient advocacy groups had accomplished, that helped us make judgments that are really complex and very dangerous judgments. All that played into the success. Then, of course, it was very rapidly approved around the world.” In this week's episode of The G Word, Dr Richard Scott, our Chief Medical Officer, is joined by Dr Stanley Crooke, M.D., Ph.D., the founder, chairman of the board and Chief Executive Officer of n-Lorem. In this episode, Dr Scott and Dr Crooke discuss the foundation of n-Lorem, the importance of patient advocacy groups and the spinal muscular atrophy treatment Spinraza. They also discussed the value of whole genome sequencing in newborn screening.

SMA News Today's multimedia associate, Price Wooldridge, reads an article about how a small group of children given the gene therapy after Spinraza's start showed only slight further gains; early treatment most important. Also, in her latest vlog DeAnn Runge explores the topic of furry friends. Pets are an important aspect of her life. She explains how she feels pets can benefit the lives of anyone living with SMA. Watch here: https://youtu.be/9Etax9E4cH0 Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/.

SMA News Today's multimedia associate, Price Wooldridge, discusses how surgery to correct kyphoscoliosis — an abnormal curvature of the spine found in children with SMA type 1 — also allows Spinraza treatment. As Ari Anderson prepares himself for upcoming surgery, he looks for a suitable mantra to help get him through the fight ahead. In his recent article, “Preparing for Surgery, I Search for a New Mantra,” he chronicles why he needs surgery and how having a phrase to help boost his morale is helpful to maintain that fighting spirit. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/.

SMA News Today's multimedia associate, Price Wooldridge, discuses how a study in symptomatic SMA children suggests Spinraza also works to return development to these nerve cells, especially if given early. Also, with a vaccine mandate looming, DeAnn shares how this adds stress to an already difficult situation where retaining caregivers is concerned. She points out that wage restrictions and the nature of the job itself already make finding reliable staff difficult. Adding a vaccine mandate on top of that makes it virtually impossible. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

BIG NEWS! https://www.businesswire.com/news/home/20220110005334/en/ FIVE KEY LINKS - Dr. Kaye's presentation - Listen to it again and again https://investor.stoketherapeutics.com/events/event-details/40th-annual-jp-morgan-healthcare-conference - AES 2018 Poster https://www.stoketherapeutics.com/wp-content/uploads/Stoke-Poster-Dec-1.pdf - STOKE Patent https://patents.google.com/patent/WO2017106377A1/en - #OneYearSooner - How we can make clinical trials happen faster https://www.syngapresearchfund.org/post/oneyearsooner - Sign up for Ciitizen - www.Ciitizen.com/SYNGAP1 SPREAD THE WORD Twitter.com/cureSYNGAP1/status/1480546972645793794?s=20 Linkedin.com/feed/update/urn:li:activity:6886314132866506753 Facebook.com/cureSYNGAP1/posts/946801809535615 WHO IS WHO AT STOKE https://www.cshl.edu/research/faculty-staff/adrian-r-krainer/ PhD Harvard 1986 https://www.linkedin.com/in/huwnash/ PhD Harvard 1997, EIR ATP since 2014 https://www.oligotherapeutics.org/officers/isabel-aznarez-ph-d/ PhD Toronto 2006 https://www.linkedin.com/in/barryticho/ MD PhD Chicago https://www.linkedin.com/in/edward-kaye-0a46a710/ MD Loyola Chicago COMPANIES Stoke https://www.stoketherapeutics.com/ $ACAD Acadia https://www.acadia-pharm.com/ $STOK OTHER GREAT LINKS DSF on the Monarch https://www.dravetfoundation.org/wp-content/uploads/2020/04/Stoke-Community-FAQ-April-2020.pdf It starts with Spinraza https://www.ninds.nih.gov/About-NINDS/Impact/NINDS-Contributions-Approved-Therapies/Nusinersen-Spinraza%C2%AE-%E2%80%93-Spinal-Muscular aka https://en.wikipedia.org/wiki/Nusinersen Grant made in 2003, Phase 1 in 2011 (dec) FDA approval in 2016 (Dec) https://www.curesma.org/fda-approves-spinraza-for-sma/ From: https://www.bizjournals.com/boston/news/2018/01/04/ex-sarepta-ceo-takes-helm-of-genetic-disease.html Stoke Origins: https://endpts.com/gene-therapy-startup-stoke-therapeutics-secures-another-90m-in-series-b-funding/ $40M from ATP in 2018. https://www.appletreepartners.com/portfolio#stoke-therapeutics IPO June 2019 $163M/ https://www.spglobal.com/marketintelligence/en/news-insights/trending/OTV6RnpzTCGYyRs_gx1m7A2 REMEMBER Raise funds at https://syngap.fund/give Sign up for this 10 minute #podcast #SYNGAP10 here https://syngap.fund/10 if you want a direct link for Apple: https://syngap.fund/10a Episode 43 of #Syngap10 - January 14, 2022 #StokedAboutStoke #ASO #SYNGAP1 #AcadiaPharma #StokeTx #F78A1 #Syngap #epilepsy #autism #intellectualdisability #id #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #Genetics --- Send in a voice message: https://podcasters.spotify.com/pod/show/syngap10/message

Stoke Therapeutics & Acadia Pharmaceuticals are working on SYNGAP1 BIG NEWS! https://www.businesswire.com/news/home/20220110005334/en/  FIVE KEY LINKS - Dr. Kaye's presentation - Listen to it again and again https://investor.stoketherapeutics.com/events/event-details/40th-annual-jp-morgan-healthcare-conference - AES 2018 Poster https://www.stoketherapeutics.com/wp-content/uploads/Stoke-Poster-Dec-1.pdf - STOKE Patent https://patents.google.com/patent/WO2017106377A1/en - #OneYearSooner - How we can make clinical trials happen faster https://www.syngapresearchfund.org/post/oneyearsooner - Sign up for Ciitizen - www.Ciitizen.com/SYNGAP1 SPREAD THE WORD Twitter.com/cureSYNGAP1/status/1480546972645793794?s=20 Linkedin.com/feed/update/urn:li:activity:6886314132866506753 Facebook.com/cureSYNGAP1/posts/946801809535615 WHO IS WHO AT STOKE https://www.cshl.edu/research/faculty-staff/adrian-r-krainer/ PhD Harvard 1986 https://www.linkedin.com/in/huwnash/ PhD Harvard 1997, EIR ATP since 2014 https://www.oligotherapeutics.org/officers/isabel-aznarez-ph-d/ PhD Toronto 2006 https://www.linkedin.com/in/barryticho/ MD PhD Chicago https://www.linkedin.com/in/edward-kaye-0a46a710/ MD Loyola Chicago   COMPANIES Stoke https://www.stoketherapeutics.com/ $ACAD Acadia https://www.acadia-pharm.com/ $STOK   OTHER GREAT LINKS DSF on the Monarch https://www.dravetfoundation.org/wp-content/uploads/2020/04/Stoke-Community-FAQ-April-2020.pdf  It starts with Spinraza https://www.ninds.nih.gov/About-NINDS/Impact/NINDS-Contributions-Approved-Therapies/Nusinersen-Spinraza%C2%AE-%E2%80%93-Spinal-Muscular aka https://en.wikipedia.org/wiki/Nusinersen  Grant made in 2003, Phase 1 in 2011 (dec) FDA approval in 2016 (Dec) https://www.curesma.org/fda-approves-spinraza-for-sma/  From: https://www.bizjournals.com/boston/news/2018/01/04/ex-sarepta-ceo-takes-helm-of-genetic-disease.html Kaye said he was recruited by Stoke co-founder Adrian Krainer, with whom he previously worked at Genzyme before joining Sarepta in 2010. Krainer is perhaps best known for being an inventor of another “antisense” drug targeting a genetic disease, Biogen's spinal muscular atrophy treatment Spinraza. “He was one of the real originators of RNA therapy,” Kaye said. “I thought (Stoke) was at a point where it needed to be shepherded from preclinical development into the clinic. It was a really exciting opportunity.” Stoke Origins: https://endpts.com/gene-therapy-startup-stoke-therapeutics-secures-another-90m-in-series-b-funding/ $40M from ATP in 2018. https://www.appletreepartners.com/portfolio#stoke-therapeutics  IPO June 2019 $163M/ https://www.spglobal.com/marketintelligence/en/news-insights/trending/OTV6RnpzTCGYyRs_gx1m7A2  REMEMBER Raise funds at https://syngap.fund/give  Sign up for this 10 minute #podcast #SYNGAP10 here https://syngap.fund/10 if you want a direct link for Apple: https://syngap.fund/10a  Episode 43 of #Syngap10 - January 14, 2022   #StokedAboutStoke #ASO #SYNGAP1 #AcadiaPharma #StokeTx #F78A1 #Syngap #epilepsy #autism #intellectualdisability #id #raredisease #epilepsyawareness #autismawareness #rarediseaseresearch #SynGAPResearchFund #CareAboutRare #PatientAdvocacy #GCchat #Neurology #Genetics

SMA News Today's multimedia associate, Price Wooldridge, discusses how Spinraza improved fine manual dexterity in both hands of five children with SMA type 2 over 1.5 years of treatment, a case series shows. As the new year gets underway it's a great time to hear what motivates people. In Ari Anderson's recent column, “The Blessings That Spark My Ambitions for the New Year,” he talks about an opportunity that fell into place and how he's using that to propel future achievements. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

SMA News Today's multimedia associate, Price Wooldridge, reads a news article on how the delays in Spinraza treatment due to the COVID-19 pandemic did not directly result in worsening symptoms in children, a study in Italy says. Also, after reflecting on 2021, DeAnn shares what her plans are for 2022. Although she doesn't make resolutions, she's made goals and explains what they mean to her. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

SMA News Today's multimedia associate, Price Wooldridge, discusses how not having Spinraza therapy as prescribed – called treatment non-adherence – increases overall costs and healthcare use for SMA patients. Also, DeAnn Runge shares why December is a bittersweet time of the year. Despite that she's looking forward to the upcoming year. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

SMA News Today's multimedia associate, Price Wooldridge, discusses how delays of Spinraza treatment due to COVID-19 seem to affect children's function less than weaker family support, small study found. Plus, togetherness is something Alyssa Silva looks forward to during the holiday season. In her latest SMA News Today column, “Cherishing Togetherness During the Holidays,” she shares some of their family holiday traditions as well as points out why she cherishes them. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

SMA News Today's multimedia associate, Price Wooldridge, discusses an article about how blood levels of neurofilaments and the results of a nerve-muscle test may be biomarkers for SMA onset/severity and treatment response. Also, Sherry Toh's SMA News Today article, “As an Adult With SMA, I Need Access to Evrysdi, Too,” pulls at your heartstrings. DeAnn can relate to those feelings as it reminds her of when she was trying to access Spinraza. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

SMA News Today's multimedia associate, Price Wooldridge, discusses an article about how administering Spinraza by subcutaneous intrathecal catheter improved upper limb function in some spinal muscular atrophy patients. Plus, there are differing opinions on how to refer to a person with a disability. Halsey Blocher's recent column discusses this topic and talks about how there's not one right answer. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

My take on risdiplam vs Spinraza as someone with spinal muscular atrophy type 3 --- This episode is sponsored by · Anchor: The easiest way to make a podcast. https://anchor.fm/app Support this podcast: https://anchor.fm/smainvisiblelife/support

SMA News Today's multimedia associate, Price Wooldridge, discusses how Spinal Muscular Atrophy (SMA) children not helped by Zolgensma, are being enrolled in the Spinraza RESPOND trial. Plus, usually Kevin Schaefer reads his own columns, but today DeAnn Runge has the opportunity to share his latest column. Titled, “Embracing a New Chapter in Life With SMA,” Kevin writes about his longtime caregiver leaving and all the emotions surrounding it, of course putting his unique spin on it. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

SMA News Today's multimedia associate, Price Wooldridge, discusses a trial planned of Spinraza at high dose in Spinal Muscular Atrophy (SMA) patients who have used Evrysdi. Read the news article: https://smanewstoday.com/news-posts/2021/09/17/high-dose-spinraza-trial-sma-patients-using-evrysdi/ DeAnn Runge doesn't shy away from personal topics especially when she feels others can relate or offer advice. One of the added challenges, when you have a disability, is dealing with your period. She talks about how she manages it, but also discusses why she's looking for alternative options. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

Our guest this week is Chad Lunt of Menlo Park, CA. Chad is married to Cherisse and they have three children including Lucy, age 12, who has Type 1 Spinal Muscular Atrophy. We'll hear how the Lunt family through their faith, along with help from the Tess Research Foundation, the Gwendolyn Strong Foundation and the miracle drug Spinraza has helped Lucy overcome. And about their hopes for the future in this Special Fathers Network Dad to Dad Podcast.Tess Research Foundation - https://www.tessresearch.org Gwendolyn Strong Foundation - https://nevergiveup.org Email Chad - chad.t.lunt@gmail.comCherisse's Instagram: @chertluntSpecial Fathers Network - SFN is a dad to dad mentoring program for fathers raising children with special needs. Many of the 500+ SFN Mentor Fathers, who are raising kids with special needs, have said: "I wish there was something like this when we first received our child's diagnosis. I felt so isolated. There was no one within my family, at work, at church or within my friend group who understood or could relate to what I was going through."SFN Mentor Fathers share their experiences with younger dads closer to the beginning of their journey raising a child with the same or similar special needs. The SFN Mentor Fathers do NOT offer legal or medical advice, that is what lawyers and doctors do. They simply share their experiences and how they have made the most of challenging situations. Special Fathers Network: https://21stcenturydads.org/about-the-special-fathers-network/Please support the SFN. Click here to donate: https://21stcenturydads.org/donate/

Dan Temple is a patient advocate for those with Spinal Muscular Atrophy (SMA) and he shares his treatment journey and actions he has taken to raise awareness about SMA.  We also talk about the drug treatments that have come onto the scene since he was first diagnosed when Dan was 2 years old.  He is now 49. Dan says, "Like I said, very important was that my lung function improved. I probably gained about ten years back from what I lost. I'm still on a feeding tube, but I couldn't eat by mouth for seven years, and the drugs helped my muscles start working better. So I can eat and drink by mouth a little bit. I don't do it a lot, but it's nice to be able to do it occasionally and have some food that I enjoy. And my hand, of course. The one finger I have is kept pretty strong. Thank God because if I lose that, I've got nothing." "In general, it's kept me from getting worse, and when the drugs came along, I was at the point health-wise where I probably didn't have a lot of time left. My lungs were getting so weak that I was going to have to be on a respirator soon. So, basically, the Spinraza and Evrysdi both saved my life and gave me another 20 years, probably." #SMA #SpinalMuscularAtrophy #RareDisease #Evrysdi #Spinraza #MDA #MuscularDystrophyAssociation #PatientAdvocate #Genentech #Biogen #SMAAwarenessMonth  

Dan Temple is a patient advocate for those with Spinal Muscular Atrophy (SMA) and he shares his treatment journey and actions he has taken to raise awareness about SMA.  We also talk about the drug treatments that have come onto the scene since he was first diagnosed when Dan was 2 years old.  He is now 49. Dan says, "Like I said, very important was that my lung function improved. I probably gained about ten years back from what I lost. I'm still on a feeding tube, but I couldn't eat by mouth for seven years, and the drugs helped my muscles start working better. So I can eat and drink by mouth a little bit. I don't do it a lot, but it's nice to be able to do it occasionally and have some food that I enjoy. And my hand, of course. The one finger I have is kept pretty strong. Thank God because if I lose that, I've got nothing." "In general, it's kept me from getting worse, and when the drugs came along, I was at the point health-wise where I probably didn't have a lot of time left. My lungs were getting so weak that I was going to have to be on a respirator soon. So, basically, the Spinraza and Evrysdi both saved my life and gave me another 20 years, probably." #SMA #SpinalMuscularAtrophy #RareDisease #Evrysdi #Spinraza #MDA #MuscularDystrophyAssociation #PatientAdvocate #Genentech #Biogen #SMAAwarenessMonth

August is SMA Awareness Month so we had a conversation with Nick Sinagra to learn about SMA and his journey with this rare disease.  Nick is a true leader for all the things he has accomplished and continues to accomplish, and for the attitude he brings to all that he does.  Plus hear about Nick's experience with Spinraza, a drug developed and FDA approved to treat SMA.

August is SMA Awareness Month, so we had a conversation with Nick Sinagra to learn about SMA and His Journey with this rare disease.  Nick is a true leader for all the things he has accomplished and continues to accomplish, and for the attitude he brings to all that he does.  Plus hear about Nick's experience with Spinraza, a drug developed and FDA approved to treat SMA. Nick's website: https://ableitpros.com/ Nick in the news: CBS Pittsburgh: The Importance of SMA Awareness Month Authority Magazine: Unstoppable Nick Sinagra Pharmacy Times: Living With and Treatment Options for Spinal Muscular Atrophy

SMA News Today's multimedia associate, Price Wooldridge, discusses improved lung function with Spinraza in a Spinal Muscular Atrophy (SMA) Type 2 child. Also, As DeAnn Runge awaits the arrival of her Jaco Robotic Arm she's doing some last minute cleaning. She even found a way to personalize her chair. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

A Tauranga couple have been forced to split up their family so their daughter can access treatment for Spinal Muscular Atrophy in Australia - treatment that Pharmac won't fund in New Zealand. They are among about ten New Zealand families who have moved countries since 2018 to access treatment for SMA. It comes as the Human Rights Commissioner calls on Pharmac to urgently review funding for the SMA drug Spinraza saying the agency's assessment of the drug is too narrow and doesn't account for the true costs to society. Investigative Journalist Guyon Espiner reports

SMA News Today's multimedia associate, Price Wooldridge, discusses how VRK1 mutations were found in two adult-onset Spinal Muscular Atrophy (SMA) Hispanics. In the forums there are a lot of great discussions going on. A topic creating a lot of buzz is the SSI Restoration Act of 2021. July being Disability Pride month is another topic with a lot of interest. Other topics include disability portrayed in media, what the line is between inspirational and inspiration porn and Spinraza injection day woes. There are also members in various stages of pursuing a Jaco robotic arm. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/ Visit the SMA forums https://smanewstoday.com/forums/

SMA News Today's multimedia associate, Price Wooldridge, discusses how Spinraza improves motor function in Spinal Muscular Atrophy (SMA) Type 3 children. In recognition of Disability Pride Month, DeAnn Runge reads the column ‘All of Us Will Become Disabled and Sick' by Brianna Albers. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

SMA News Today's multimedia associate, Price Wooldridge, discusses children with Spinal Muscular Atrophy (SMA) taking Spinraza, leanding to better swallowing and farther walking. Also, not only are the forums a great place to learn, they're a fabulous place to share where members can really relate to each other in a unique way. New categories have been added that emphasize that fact. Weekly Wins is a space to share weekly highlights and generally positive things. Would You Rather is new as well. In this forum there will be questions where you have to choose between two hypothetical situations. One of the biggest topics recently in the general forum is caregivers. Specifically how challenging it is to find them right now. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

From her TED talks and her appearances on PBS, geneticist Wendy Chung is known to millions of people as an expert on autism. But thanks to funding from the Simons Foundation, she's also known to tens of thousands of people with autism and their families as the leader of history's largest study of the genetics of autism spectrum disorder (ASD). It's called SPARK, for Simons Foundation Powering Autism Research for Knowledge, and it's a big-data exercise of unprecedented proportions.SPARK is partnering with more than 30 medical schools and research centers to recruit 50,000 families with members affected the ASD. Participants have their DNA sequenced, enabling SPARK to build a list of genetic differences linked to autism as a starting point for research on the causes and mechanisms behind the condition. At the moment the list includes 157 single genes and 28 copy number variants. But changes in these known ASD genes show up in only about 10 percent of families studied—suggesting that the existing list is just the tip of the iceberg. Identifying common gene variants with small effects requires large sample sizes, which is why SPARK aims to recruit so many participants. At 50,000, the SPARK researchers think they'll be able to find as many as 150 individuals with mutations in each of the 100 most common ASD genes.SPARK is unusual not just for its scale but for its participant-friendly design. Biospecimens such as saliva samples are mailed in, and patient data is collected through remote online questionnaires rather than in a clinic. The study also follows participants longitudinally, and it returns genetic data to them—an uncommon practice in large studies due to its resource-intensiveness.Chun trained in biochemistry and economics at Cornell, earned a PhD in genetics from Rockefeller University, and got her MD from Cornell University Medical College. On top of her role as SPARK's principal investigator, she is also the  Kennedy Family Professor of Pediatrics and Medicine and Chief of Clinical Genetics at Columbia University Medical Center.  Please rate and review MoneyBall Medicine on Apple Podcasts! Here's how to do that from an iPhone, iPad, or iPod touch:• Launch the “Podcasts” app on your device. If you can't find this app, swipe all the way to the left on your home screen until you're on the Search page. Tap the search field at the top and type in “Podcasts.” Apple's Podcasts app should show up in the search results.• Tap the Podcasts app icon, and after it opens, tap the Search field at the top, or the little magnifying glass icon in the lower right corner.• Type MoneyBall Medicine into the search field and press the Search button.• In the search results, click on the MoneyBall Medicine logo.• On the next page, scroll down until you see the Ratings & Reviews section. Below that, you'll see five purple stars.• Tap the stars to rate the show.• Scroll down a little farther. You'll see a purple link saying “Write a Review.”• On the next screen, you'll see the stars again. You can tap them to leave a rating if you haven't already.• In the Title field, type a summary for your review.• In the Review field, type your review.• When you're finished, click Send.• That's it, you're done. Thanks!Full TranscriptHarry Glorikian: I'm Harry Glorikian, and this is MoneyBall Medicine, the interview podcast where we meet researchers, entrepreneurs, and physicians who are using the power of data to improve patient health and make healthcare delivery more efficient. You can think of each episode as a new chapter in the never-ending audio version of my 2017 book, “MoneyBall Medicine: Thriving in the New Data-Driven Healthcare Market.” If you like the show, please do us a favor and leave a rating and review at Apple Podcasts.Harry Glorikian: From her TED talks and her appearances on PBS, geneticist Wendy Chung is known to millions of people as an expert on autism. But thanks to funding from the Simons Foundation, she's also known to tens of thousands of people with autism and their families as the leader of history's largest study of the genetics of autism spectrum disorder.It's called SPARK, which stands for Simons Foundation Powering Autism Research for Knowledge. The study has enrolled over 100,000 individuals with autism and another 165,000 family members. It's designed not just to advance understanding of autism's causes but to follow people over years or decades and help them lead successful lives.Chung calls it the Framingham of autism, a reference to the famous Framingham heart study that began in 1948 and is still going on today. So, talk about big data! When you're sequencing the exomes, that is, the expressed genes, of a quarter million people, and sharing all of your data back with patients, you're dealing with an unprecedented data management challenge. In fact, SPARK has so much data Chung jokes that she has to compete with Bitcoin farmers to buy new computer servers.But Chung isn't finished. She wants to keep going until SPARK has enrolled 50,000 families altogether. The hope is that with that volume of genetic data, scientists will be able to to figure out which genetic variants that contribute to autism might be amenable to treatment with new drugs molecules. And because the SPARK study is also collecting data about the lives of people with autism as they grow up and encounter all of life's challenges, Chung hopes the project will be able to provide individuals on the ASD spectrum with coaching and other forms of support.A few weeks back Wendy made time to talk with me about all that. And now here's our conversation.Harry Glorikian: Dr. Chung, welcome to the show. Wendy Chung: Thank you for having me today. Harry Glorikian: So I feel like I almost know you from watching you on PBS and watching you interact with your patients. So you'll forgive me if I'm more comfortable than, than actually meeting you for the first time face to face.Or I should say virtually, I think we've been doing this too long now. But, you know, I know we're going to talk a lot about your program SPARK today. But I'd like to sort of start with a little bit of maybe of history and some background, you know, it seems like one big question that attracts you above all.Others is the genetic basis of human disease. And so how did you first get interested in that?Wendy Chung: All right, so I'll go way, way back. I think I've always known that I wanted to go into science and medicine and tried to figure out a way to put things together. And for me, I guess the moment, and you'll be able to calculate my age from this.But the year that I started, my MD-PhD training program was the year the announcement was made that we would start the human genome project. And I knew I already had a passion. For what we call inborn errors of metabolism or metabolic diseases, but it became very clear to me that we would have insight into the genes and the genome to treat conditions like that.Plus other ones as well. And an MD-PhD program takes a long time to finish your entire training going to graduate school and medical school and residency and fellowship and all of those things. And so you could project out. that it might be as long as 15 years before I would finish my training.And if you looked at the projections for how long it would take to finish the genome, they basically converged about the same time. And I'm one of these people. I like to think that I'm a strategic planner and visionary. I don't want to sound egotistical on this, but I am a planner. And as I started planning, I thought to myself, well, this is really going to be incredible.The power that we'll have as a scientific and medical community. And this whole job description doesn't exist. You know, so we are gonna need people to be essentially, genomicist a brand new field of both science and medicine. And I kinda like puzzles. I like logic and I like having definitive answers.And that's what I think the genetics often provides us. And so it's really with the excitement of the opportunities with a brand new field along with just. The way my mind works, that this was really perfect. And, and I was lucky. I have to admit to be able to discover that early in my career. So what I start out to do almost the first day of medical school has really been what I've continued to do for my entire career.So, anyway, Harry Glorikian: well that is that's, that's incredibly lucky. I mean, I do believe in a process and a plan. I can't say that at a young age, like you, I knew exactly what I was going to do when I grew up. It seems to be in the same area of, of. Biology, but I think that's the only common theme that I would say. So this program SPARK grew out of the existing Simmons foundation called SAFARI right?The Simmons foundation, autism research initiative. You were on the board of SAFARI for a long time. And then, and then you became a program director of clinical research. Can you talk about. Why you felt drawn deeper and deeper into specifically autism research? Wendy Chung: Sure. So I'm trained as a pediatrician and a medical geneticist and a fair number of the patients that I see.And this was true for pre-existing before SAFARI or SPARK ever came along. But a lot of my patients have neurodevelopmental conditions and or autism. So it's a common reason for people coming to see us over my career. A lot has changed in terms of our ability to understand the underlying etiology, especially with the genetic etiology.And I will give credit that was in large part due to the SAFARI program at the Simons foundation, they really did have this original vision in terms of, we needed to understand the brain and behavior across for individuals across the spectrum. And that a really. Powerful tool to do that would be genetics.It's not all genetics. I want to be clear about that. And it's a wide spectrum. But I got pulled in just because of my expertise as a geneticists to advise the SAFARI program. And as you said it started out as advice and due to. Individuals who were there and got to know me and thought I might be able to contribute.in even bigger ways got sort of pulled from the outside to the inside, so to speak. And as that happened and understanding what the gaps were SPARK or Simons Foundation powering autism research for knowledge is the acronym. That was a vision realizing that to really make the. It's scientific inroads, we needed to do.We needed to think big. And that's because autism is not one condition. It's quite heterogeneous. It's quite complicated in terms of etiologies. And we really need to base, we need to have hard foundations, really solid evidence to be able to know what direction to go with the science and that genetics provides that solid foundation.Harry Glorikian: Yeah. I'd say it's, you know, I've I was trying to get ready for this. And I was trying to do as much reading as I could. And I realized like, We know, we know some things, but there's a lot we don't know. And then there's certain things that seem to trigger it and we're not, we don't fully understand what all those things.It's a very interesting sort of set of reading that I went through very quickly. So I'm probably like a millimeter deep and pretty wide compared to you. But it is interesting how. Genomics and genetics have, are really driving a lot of areas that we see right now. It's funny because I remember when someone way back in the beginning, so I'm dating myself also.It was said, why would you sequence anything? And now it's like, we, we want to sequence everything. And the information that it's giving us. So can you give us a high level explanation of what SPARK is and. How different it is from some of the previous studies of autism spectrum disorder and in terms of scale and goals.And, and when did you decide and how did you decide to embark on this? Cause it's I was reading this study. I mean, it is, it's a pretty ambitious goal. Wendy Chung: So again, At the Simons Foundation we had started out with something called the Simon simplex collection. And I think of that as sort of the first foray into the genomics, that was to give you a sense of order of magnitude about 2,500 individuals with autism.So, you know, a big, big order, you know, 20 fold difference in terms of the original goals, at least for SPARK But that was, I think of as being very careful in terms of making sure the individuals within that Simon simplex collection, they went through very extensive in-person evaluations with masterful clinicians, psychologists to make sure the diagnosis was unambiguous and then had the genomics sort of layered on top of that.And I won't get into the specifics of cost per person to run through that, but that was really, I think, of as the platinum version. And that was important for the field. To be able to have that again as a solid foundation and to be able to make some statistical arguments about what sample size did you need to be able to get to understand the entire complexity of autism.So it was definitely foundational and necessary. But in terms of being able to do that with about 2,500 individuals, you could make estimates, right? But in terms of the number of genes that would be involved in autism, it would be around the order of 500. And so that's just for, you know, a certain portion of the spectrum as well.And you can understand therefore, the complexity in terms of what we're talking about. And, and I'm just because I know there are some people who may not understand exactly what I'm talking about. Let me just be a little bit more granular. For people who come in to see me with a child with autism example, I'll have some individuals who may be non-verbal.They, they will never be verbal. That is they'll never talk. They may be able to communicate in some way, but they may be intellectually disabled. They may have. Seizures or epilepsy. They may have even medical problems associated with that. And that's one portion of the spectrum to another portion of the spectrum are individuals who are just incredible in that their mind works differently.It doesn't necessarily work in a wrong way. It just works differently. And they see the world in a different way. And oftentimes I have to say are profoundly insightful in terms of. Problem solving because they do come at it from a different direction and they do have just fresh eyes to be able to look at complex problems.So, and again, I, I want to be very clear in terms of how I'm talking about this. I don't consider autism a disease in that way. It's a difference, right. In terms of all of what we're talking about. And I want to be very clear also in terms of the genetics. Yeah. That this is not to get rid of anyone. This is not to be able to have a eugenics movement where we're trying to eliminate individuals with autism.It has nothing at all to do with that. It really has to do with understanding the underlying biology of how the brain works, because we've really been so much in the dark that people had theories and hypotheses, and they'd waste a lot of energy doing the wrong science because it wasn't based on that foundation of really.Truth with a capital T what are the molecules in the brain? What are the different parts of the brain that are involved? How does it change over time? We really needed that foundational information to go from kind of the dark ages of autism research into the modern age and era. And so in doing so that's the Simon simplex collection found, you know, allowed us to see what sample size did we need.So we started doing some rigorous statistical calculations of how many we'd need to get to that goal of having maybe not every single gene, but the majority of genes. And that's where the calculation of having 50,000 families. originally came up. And so that was our original goal to be able to scale that you know, 20 fold higher than what we'd done with Simon simplex collection.But if you started looking at number one who was able to participate, like who literally could give up a couple of days of their life to go in for these evaluations who was close enough to one of these study centers to do it it, it was. Partially an equity issue for me that I wanted to make sure everyone could get access to be part of understanding better and to be represented, because if you're not represented, your voice may not be heard in terms of the research.So part of it was from that point of view is from a convenience point of view making sure that individuals wherever in the United States, if they wanted to be in their pajamas at 11 o'clock at night, to be able to do this, they could do it. Then, and it wasn't so burdensome. So the whole process, you know, it takes maybe an hour or so to be able to register and become part of this, not to say that you can't do more than that first hour, but to start this off, it becomes easier.So it was with that and, you know, we've had, in terms of timing, we've had lots of ability to do things online that we couldn't do before. So when we first started this, you know, the internet wasn't as evolved as it is, and there's just a lot more we can do from home. And in general, one of the parts about SPARK that I think is really important is.That it's meant to capture people where they are. And so, I mean that both in terms of just the convenience of participating, I also mean in terms of behaviors. And so, again, as a clinician, I have children with autism who come into my office, who I have to admit it's a terrible experience for them. They're petrified in terms of, you know, they like it.They liked to understand what's coming. They don't like surprises. They get anxious. Being out of their elements is really hard for them. And so being able to do things where they're on their home turf, they're on their home territory and being able to capture behaviors where they really are rather than our artificial environments of being at a laboratory at a university at a hospital.All I think is really important to truly see what life is like for individuals. So we're trying to do all of those things in terms of really capturing, you know, more of accurate information, more data. So in terms of doing this, not just the one time you can come in and be evaluated, but over your life course.And so that's one of the things about SPARK is this is not a one and done type of. Snapshot of who you are. This is really thinking about a life course. And I really, I want to emphasize this. One of the other things about SPARK is not just the number of individuals, but it's the longevity of what we're planning to do.We've, we're celebrating our fifth anniversary this year. And from my point of view, we're planning on going this for a lot, lot longer. I don't know if it's going to be 50 years. I don't know if I'll last for myself for 50 years. But but, but this is, I tell people who will understand what I mean, this is meant to be kind of like the Framingham of autism.Another words, you know, being able to really see people through different changes over their life course, different stages of life, different challenges, trajectories of how things evolve and importantly, what we can do to change that trajectory potentially or support people better. So that sometimes when people fall through the cracks with young adults, especially is one area that I'm mindful of.How do we prop them up? How do we make sure that transition is easier? And so, like I said, for anyone, wherever they are on the spectrum, I think there's always some time, some place in your life where you need an extra helping hand. And so I hope this will start to provide that evidence base for where we can provide that helping hand and have the greatest potential impact.Harry Glorikian: Yeah, no, it's, it's this term we're using autism is, is, is quite captures a very broad set of. People as, as you indicated, like, you know, you know, Elon Musk recently got up on SNL. Right. And you had to know that he was a little off anyway before that, but, you know, I actually believe that people like that can see the world in a certain light, through a certain lens that a lot of other people would be like, I have no idea what you're talking about.I can't see it. So. All of these people, right on one spectrum or the other, which I think all of them add value as, as they're going through their lives. But the other interesting part of this study is you guys are sharing the results with participants, right. Which is not usual and not, I don't think trivial to do.So. You've got a unprecedented level of engagement and data returned to individuals and their families. You're not just returning genetic data, but aggregate reports, which in accessible language, which, you know, I'm trying to re I just finished my third book, trying to write it more accessible, of our world and I can tell you that was truly challenging.So I, what was the philosophy behind that? And what are your challenges around trying to do that?Wendy Chung: Right. So you're, you're absolutely right. I, I think in a very good way, we've been from the very beginning, and even in the planning stages of this had participants as part of that planning process and they still are literally on our staff on everything that we do, they are integrated on our teams.So let me paint a picture for you. About some of the details of what you're talking about. So as of this morning, as an example, we have over a hundred thousand individuals with autism in SPARK. We have over 265,000 total participants. So the reason why the difference for those is some of those are.Parents for instance of individuals with autism or siblings because we do encourage families to participate. So you can see that this is massive, right? This is over a quarter of a million people that we're trying to be able to in some way, juggle with all of this. And so for me, that was, you know, I don't unlike.Most of my other research studies. I don't personally know every single person in the study. I never will, unfortunately, but we do have anchors of 31 clinical sites around the country. So that's one of the things that we do to make sure that we have our finger on the pulse in some way of our participants.But I will also admit you could just be, like I said, in your jammies at 11 o'clock at night tonight and Google SPARK for autism and be able to find and sign up for this, you know, there's no, you don't have to be at one of these sites to do this. You're right. That the philosophy I heard from our participants from the very beginning, and some people may have heard this term is nothing about us without us.And so in terms of research, the idea that we want to be as research participants, we want to be part of the research team. We want to be able to have a voice we want to help you do your job better as researchers. So, you know, it's not just in a selfish way. It's about, what's going to really make us committed to doing this, not as a one and done study, but as the picture I painted to be able to continue to participate for decades forward. And so in hearing that then in hearing what was important to participants, keeping in mind that I can't do everything for everyone, you know, we have to have compromises in this. It became important for people to have access to their genetic information.But not just like, give me a flash drive with my raw data. Right. That's not helpful. If you're interpreting this information to understand genetic causes of autism and you find that for me, let me know about that. And in addition, and I, I am proud of the way we did this. We did this, not with just sort of sending someone, an email and sending, okay, well, guess what, you've got to SHANK3 variant, and this is the cause of your autism.We do this. And I think about this for myself, what would I want to do for me? What would I want to do for my family? If this were my son, how would I want this done? If I weren't a geneticist? And so we've built in I call it, choose your own adventure, but we give people choice in the sense that. When we return, number one, it costs no one, anything.Let me be very clear about that. So it's not like you're buying a test or anything. If anything, we will not. If anything, we do give you a token of a gift certificate to thank you for your time, because we know it takes time to be able to do this, but we pay for everything with this. And so we do it.For those that are aficionados. We do a process called exome sequencing to be able to look at comprehensively across the genome as we do this. And it's about right now as of today, about 10% of our participants, where we find something that we can be pretty certain is the cause of the autism in the family.And we. Again, pay for this ourselves to have a second group of people. Double check, make sure it's correct. And then the choose your own adventure is either you can choose to have your own doctor to give you that information back and explain it to you. Or if you don't feel like your doctor is the best person to do it, because maybe they're not a geneticist, maybe they don't have any idea what we're talking about.We pay for the study centrally to have a trained set of genetic counselors, be able to return the information. And I, and my team have personally written out what we call brochures in. As you were talking about lay person language that describe each one of the over a hundred conditions that we now return.And so it was a lot of work to write each one of those brochures for each one of those conditions. And to keep them up to date, but. That's how committed we are to this community. That's how important I think it is. Harry Glorikian: I, I almost feel like I need to sit down. That's just the enormity of that task is, is is extremely commendable.I can't believe I'm getting a commercial enterprise like to do that. Right. Is, is not trivial. So. That's that's incredible. Wendy Chung: This is like the Ginsu knife set, but wait, there's more! So we also appreciate that not everyone is going to have a genetic result. And so we also have parents for instance, that are completing questionnaires that tell us about how their child is doing in terms of behaviors or you know, things that are related to autism or behavioral issues.And I have to say during COVID as well, Especially, this was a big issue for many people, not just individuals with autism but about psychological differences and making adjustments during COVID. So within that we give and these are again, standard psychometric tests that are used so-called in the industry.So in other words, by psychologists who are practicing we give that information back to families. We use infographics. And so all of this has been test driven in plain language with groups of individuals that are average parents, individuals with autism. We have a commendable group of about 80 of our participants that sit on our board again, giving us feedback before we go live with any of this, telling us how to tweak it, to make this more accessible, using different infographics, to be able to make this easy.But every one of those things that we can return, then. We return it to our participants. We have something called a research match program. So we have over 150 researchers who use SPARK as a way of letting the community know about the research they're doing and being able to match SPARK participants with research so that this is, as you can see, it continues to kind of organically grow, not just SPARK, but the entire research community.And a requirement for every one of those researchers is that when they complete their research, they have to actually give that information back to the people who participated in the research, into the SPARK community, in lay language. So in a way that families and individuals. Can access and understand it.And we have many of them give webinars or be featured in our newsletter, but the whole process is we're learning together. And I want, I want people to see how science is done. I want them to be part of like the front lines. Like they're getting the preview in terms of hot off the presses information.So with this, hopefully this is a movement in science. It's not just SPARK. I hope all, all people do this. Harry Glorikian: I was going to say, I think you need to teach a master class on how to do this because. I'm not familiar. Maybe somebody else is doing it, but I'm not familiar with it. Usually I get gobbledygook back.I mean, I just actually volunteered to do a diagnostic clinical trial and it was, and I'm in the, in the business and I was reading what they wanted and I was like, I don't understand this at all. I don't understand what you want from me. I don't understand what I'm going to get back. I don't understand anything.I'm not participating. I don't have time for this. So but all the stuff you said now really rings in my head of A), a data management challenge, B), analytics challenge, and C), how do you automate some of this? Because the first thing that goes into my head is is there, you know, some aspect of AI or machine learning that can do some of this because.If I'm not mistaken, every time you discover more variants, you're going back and reanalyzing the genomic data. And that becomes exponentially a bigger and bigger task. If there isn't some level of automation to sort of make part of that more turnkey. So what are you doing there? Wendy Chung: Yep. So you're absolutely right about you know, we have thought about ways to scale.This scale is one of my favorite words right now. Because you're right, that each time we get more people that come in and more data, we turn, we, you know, turn the crank. One more time. Knowledge is increasing around us about the brain and behavior. We're adding that and putting that back in, and then again, increasing the robustness of what we do.And we do want to be really rigorous in terms of as we're doing this. So that's on the genetic side. And so there are. Our ways of being able to do that, I will say it takes more and more in terms of computing time or sort of, you know, person power to do this Bitcoin, by the way has been a problem.They're buying a lot of servers. They need to, you know, free up some of those for science anyway. But aside from that there's also the issue in terms of people report to us behaviors and in an interesting way. And it's just kind of what happens when you do science this way. Not everyone is perfect in terms of how they.Decide to participate and I get that. And so what I mean by that is there's missing ness of data that we as researchers have, you know, we realized that we've used the machine learning and some ways to fill in those missing pieces. And so what we've tried to do is use machine learning. I talked about a spectrum for instance, and people are at different ends of the spectrum that ends up being incredibly important to interpret the genomic information, as well as information about other people in the family.And yeah. How their genetics go with their own particular place on the spectrum. And so putting all that together, we can get a profile with machine learning, to fill in some of the gaps, fill in some of the blanks, understand issues with trajectory, and then combine that with the genetics. And so the good thing, and this is another reason why we set up SPARK the way it is.I'll be very clear to anyone who's thinking about this, either as a contributor, as a user. Everything is de-identified of course. So no one knows who any participant is, but I, I set this up originally so that the broad research community would be able to think about these problems. And I tried to de-risk it for any scientists who wanted to enter this.So as a data scientist, for instance, You may not be an expert in autism, but I want you to be able to contribute in terms of doing this. And so the way this is set up again is the entry to access this as you do. We make sure you're a real bonafide researcher. We do go through a rigorous check of that, but you don't have to be an autism researcher.You could be in industry, you could be an academia, you know, you could be at a private foundation. We just want to make sure you're doing good science. And I have been saying that many of the people who are using the data. are not necessarily, they didn't start out as autism researchers. They simply are data scientists, computational biologists, who are able to look at the data in interesting ways.And I think the more we can bring smart people to the table on this, the faster we'll get some of the answers we need. [musical transition]Harry Glorikian: I want to pause the conversation for a minute to make a quick request. If you're a fan of MoneyBall Medicine, you know that we've published dozens of interviews with leading scientists and entrepreneurs exploring the boundaries of data-driven healthcare and research. And you can listen to all of those episodes for free at Apple Podcasts, or at my website glorikian.com, or wherever you get your podcasts.There's one small thing you can do in return, and that's to leave a rating and a review of the show on Apple Podcasts. It's one of the best ways to help other listeners find and follow the show.If you've never posted a review or a rating, it's easy. All you have to do is open the Apple Podcasts app on your smartphone, search for MoneyBall Medicine, and scroll down to the Ratings & Reviews section. Tap the stars to rate the show, and then tap the link that says Write a Review to leave your comments. It'll only take a minute, but it'll help us out immensely. Thank you! And now back to the show.[musical transition]Harry Glorikian: Did you ever think when you were getting your MD-PhD that you'd have to become a data scientist or an IT manager? Wendy Chung: So not exactly. And in fact, so anyway, I'll tell you sort of how I grew up. I was actually as growing up, if you had asked me what my natural proclivity or skill was, I was definitely mathematically inclined.It was very data science inclined, very mathematically inclined. And. Probably even too good in some ways for my own shoes. Cause I kind of got ahead of myself in terms of taking very advanced courses at an early age it was, I'll never forget this conversation though. I had a discussion with my math professor as an undergraduate and said, you know, I'm really good at this stuff, but what can I do with a degree in math?And he said, oh, well you can go work at an insurance company. You can be an actuary. You can. You can figure out what rates, you know, people should be paying in terms of their insurance. And I said, Really that's what you do with a math degree. And like, literally I did a 180 pivot and said, that's not worth, you know, going into for that.And that was, I have to admit unfortunate and, and, you know, I, I'm not saying everything happens for a reason. I have no regrets in terms of what I've done with my life. I think that, you know, I found my home and, you know, a great thing to do. But I do have some regrets that, you know, He had that influence on me in that way.So, you know, I could've seen myself the time when I grew up, you know, we were just starting to have personal computers, you know, we were, we didn't even have emails or internet or, you know, it's a completely different world than when I was training. So I will admit. That a lot of what I do is done by others.I think that's a good thing. I will say team science is incredibly important. And even though I'm here talking to you today, really I'm representing literally hundreds of scientists behind the teams that are actually doing the hard work, whether it's coding, to be able to make our interfaces for users valuable, whether it's data scientists analyzing the data, psychologists neurobiologists, you know, there are just amazing people that are behind the scenes doing all of this.And so when it comes to a lot of the really heavy lifting. I will admit that they're the ones doing the heavy lifting and, you know, in a good way, I think I've got the vision to guide the ship. But there are a lot of really smart, especially young minds that are driving a lot of the science. Harry Glorikian: So I want to switch here and switch to recruitment here just for a minute or so, because I also want to ask some of the listeners to point people in, in the direction of this study.Right. Dump more people the better, but W w where are you now from a numbers perspective? The last numbers that I saw were. 18,000 individuals in 2017 and 28,000 family members on top of that, I'm sure it's grown since then, but w what are the numbers right now? Wendy Chung: Yep. So, as I was saying, you know, the numbers are in terms of people registered just over a hundred thousand with autism and just over, it's about 265,000 total.So I'm not gonna. Anyway, I'll I'll go ahead and just say it. So there are individuals who get stuck at various different stages in the process. I will say, dads seem to get stuck more than moms do, and I can understand dads are busy. But when I, some of the numbers you were quoting, for instance, we have registration.We also have send out a saliva kit for people to be able to donate a DNA sample. So they spit in a tube and they send that back. And so we have a fair number of people that get stuck at that point and dads in particular. Yeah. When we started out the sequencing, one of the things that I'll just give a little science behind this is that we call them Denovo genetic variants.So variants that are brand new in the individual with autism are oftentimes some of that 10% that we'll recognize as a cause of autism. I'm not saying those are the only causes, but those are the ones we recognize at this point. So it became a, and has always been really critical to have both mother and father and the individual with autism whenever possible, so that we.You could very quickly recognize what was different in the child with autism, from either their mother or father, having them in comparison, just like makes that sort of crank we were turning about very easy to turn. We've had issues in terms of being able to get, and I call it, we call them dangling dads.But dads that, you know, just haven't quite gotten it together and have found the time or found their kit to send that back in. And that has decreased the number of family units, mothers, fathers, and children with autism that we can look at. And so. has limited. Some of the analysis that we do on the other hand, as I said, we want to make sure everyone that contributes is able to contribute.So we have our analyses now include every single person who's contributed a saliva sample to SPARK, at least a, you know, saliva sample that's been sufficient to be able to sequence. So whether it's just one person or one person in their mother or one person and their father, everyone is represented in what SPARK does.Just a question, as I said, of what we can recognize I do want to call out and this may or may not be obvious to listeners, but I do want to call out. It is really important for everyone to be represented because of the number of types of autisms. But also I think it's an equity issue in terms of ancestral diversity.So where in the world. Your family came from, if they came from China, if they came from Brazil, if they came from Ghana, wherever in the world, they came from, it's really important because the genetic variants from our ancestors differ depending on where in the world you came from. And right now, in terms of genetics, about 80% of the genetic data we have as part of research comes from individuals from about 20% of the world's population.And so we are. Overrepresented for individuals of European ancestry, which means that in terms of being able to recognize those genetic factors, we do a pretty good job. If you're of European ancestry, we don't do nearly as good a job, though. If your family comes from other parts of the world and. Both in terms of equity and making sure that we don't increase this gap in terms of genomic medicine and utility of this information.It's really important to me that everyone gets the same shot at this. And that's part of, like I said, why we made this so easy for people. And I hope they'll take advantage of that because some people won't get this information any other way,Harry Glorikian: We need to be inclusive of everybody, but when I look at the trajectory and the, and the.How all of these technologies across a number of different areas, that seems to be a common theme is, you know, who accessed it first? Where do we have the most data and what do we need to do next? And I, I look at the, all these technologies as on an evolutionary scale, right? Where, where we're, we're continuing to add and how do we get to more people?How do we make it easier for people to participate, et cetera? Cause. When we were at applied Biosystems and there were sequencers right there. I mean, you could just, it was pretty easy to participate. Whereas for other people who don't have access or it's not as, I mean, if D'Souza at Illumina does what he wants to where he's, he's talking about a $60, whole genome.There'll be things that we'll be doing that we haven't even thought of yet. Wendy Chung: Absolutely. And we've thought of some of those things. So the next time you have me on, we'll talk about some of those others. But, but I, you know, in So, although there's the accessibility, I do think there are some issues, understandable issues about trust.And do I want you to have my genome? Do I trust you to have my genome? You know, could you do something Is some police officer going to arrest me or, you know, try and somehow plant evidence. That's going to be used against me in some way. So I think there are all sorts of reasons why certain members of our community don't feel comfortable with them.Participating and I totally get that. I think part of it is I want to make it easy for people. I also want to make sure and it's through SPARK that we're doing, this is to understand and have those individuals have a seat at the table, be able to address as many of those concerns as we have. So we can build that trust and build that, you know, shared vision and shared goal in terms of moving the science forward.And I say this and it's slightly different. I'm going to slightly digress, but I also, as a geneticist, for instance Treat patients for instance, who have cancer or have a family history of cancer. And I'll just very briefly share a story, which is that I had a patient who happened to be of African-American ancestry.And she actually through a very long I'll just long story short had a family history of breast and ovarian cancer. And although she did the sort of BRCA tests that some people talk about BRCA1 and 2, she did not really get the full. Understanding of the information from that test because she had a genetic variant that at the time wasn't recognized it happened to be a real true, what we call disease causing variant to increase the risk of breast and ovarian cancer.But it wasn't recognized because her community, her individuals from the same ancestry, weren't represented to be able to distinguish sort of the signal from the noise if you will. And so that's what happens in terms of, and she ultimately went on to develop. Metastatic cancer, unfortunately. And so there's this gap that has been evolving and actually gets wider and wider with the more that we depend on using genomic medicine, either to select the right medication or be able to decide what preventative treatments or what increased screening to do.There becomes a wider and wider gap between the haves and the have-nots. And I, I just want to make sure we narrow that gap. We get back to being equitable. Harry Glorikian: I totally agree. I mean, I have my own pet peeve stories about BRCA I mean, I was lucky enough to do I helped Myriad with some of their strategies and, you know and I got to learn a lot about their database versus everybody else's database.And so I have my pet peeves on where people should go and get their testing. But I also agree that being able to explain this to someone. Is not trivial. That person didn't fall off the turnip truck. Right. And the data is changing daily. I used to be able to turn on my computer and I'd be like, oh, I can keep track of that one and keep track of it.Now it's for forget it. If I don't have IT support. Hmm. And somebody who's been studying it it's, I don't want to say it's relatively impossible, but it's extremely daunting. To sort of keep up with what's going on. Wendy Chung: So let me just I'm going to stay on that note, although it's not directly SPARK related.There's some listener out there who would this'll resonate with your point of scalability and to be able to wrangle all of that changing interpretation of the data in real time is very important to me because like you said, there's a lot that we don't yet know what it means, not just related to autism, but related to a lot of the way our bodies function.And there needs to be a platform and informatics system that facilitates that you as an individual to your doctor would be great. But you also, as an individual can contribute to and engage in to be able to manage your own health. Harry Glorikian: So I have to tell you, I mean, after all the work I've done and everything that I've tried to write and so on and so forth, this whole idea that everybody has, that they're going to have their individual silos is to me, a bunch of malarkey, right?We've all seen that when you put all the mapping information and Google has it, it's an exquisite piece of, you know, useful database that you get you around tells you where you need to go, what you need to do. It's not. there aren't 50 of them or a hundred of them. I mean, in our world, if I think of everybody's individual silos, there's thousands of them.And it should be, I mean, the country itself needs to aggregate this. I know that medical professionals will be like, no, it's my data. It's not your data. It's the patient's data. And it should be aggregated. And by aggregation, we can gain more insight into it, but, you know, These are policy issues that every once in a while, I try to influence people on.But boy, they, they, the technology is moving much faster than the understanding of the people that are writing the policy and not to digress. But I think if we want to solve problems or at least gain a deeper understanding until we do that, I think it's just going to be chipping away except for programs like yours or certain companies that I know that are spending the money to.Build a massive data set that they can then sift through. But all of this work that you're doing is to diagnose the patient better, manage the patient, better, understand the progression of PA of the patient, but it's also to eventually I'm assuming design certain drugs or, or certain therapeutic interventions that, that, that w w where are you from?In that standpoint. Wendy Chung: Yep. So we are moving forward. It's not going to happen overnight, but I talk a lot about getting people to the starting line. So we have a sister study for SPARK called Simon Searchlight. That's actually, we've been doing that for about 10 years. That now is once you get a diagnosis, a genetic diagnosis, the point is then you've got a group of individuals that all share that same genetic diagnosis.You can learn from each other. You can learn from researchers. And to your point now, you know what starting line and what race you need to line up for. Right? Because you're in terms of a treatment or a support, it's likely to be specific. There may be some commonalities across genes, but in some cases, if you think about a gene therapy or gene editing or gene replacement or something like that, That is going to be at the level of specificity, at least at the gene.And in some cases, maybe even by the genetic variant. So in terms of doing that number one is that I do think this is going to be, I call it a step function mathematically, right? So there are going to be enabling technologies. And when certain enabling technologies and delivery systems are in place, they're going to be, it's not just going to be one condition.That's now treatable. It's going to be a whole class genetically of conditions that are treatable. And it's a matter of as modules popping in the right gene into that system and making sure that the window of opportunity for treatment is still open. But as we're doing that, it's important to me that even for conditions that are seemingly very rare, they're in the aggregate.Quite common. And there are a lot of lessons to be learned from each other as we're doing that. So it's kind of getting everyone lined up. We're starting to think about, and I don't want to put a timeframe on it, but it may be as soon as within the next year or two, that we'll be starting to actually use treatments.In some of the individuals, either in SPARK or Simon Searchlight with one of those genetic events that's amenable to some of these molecular technologies. We have a clinical trial for something called R-Baclofen that got shut down by COVID, but hopefully we'll be opening up again soon. And that will be it's a small molecule or a pill that you'll take.But for certain individuals with a particular group called 16P11.2 deletions, again, one genetically defined group. But that clinical trial, I hope will be opening up in later in 2021. So we are marching forward towards treatments. We also think of, as I said, supports for individuals.So it's not just about changing the person or giving them a drug. But thinking about, you know, what do you need? Is it that you need coaching in terms of how to, you know, ask someone out on a date, how to be able to interview for a job, how to, you know, be able to get your life together, to go off to college and live somewhat independently, you know, Things like that, that may be a little bit more difficult for certain individuals.But how do we deal with some of those things as well? All of these I think are going to be incredible opportunities. And like I said, a large part of what I do is try and de-risk all of this. So think about the research community. What does the research community need? What are we going to need for FDA registration?How can I make this easier, more accessible? Like how can I. What are the tools I can put in the toolkit so that if someone has got a hammer, I can point them to all of these nails out here that they can just start hammering one by one and be able to hopefully make a much bigger impact than they could if they just, you know, saw one nail that they could hit.But with this, like I said, it's not going to happen overnight. It's still, I think, you know, when I think back to the last year of what we've had in terms of molecular therapies, you know, things like Spinraza and spinal muscular atrophy have been truly revolutionized you know, what used to be for me, the most common genetic cause of death for infants is now something that we do with.Newborn screening and we have a one and done gene therapy. I mean, it's just remarkable. I, I never, in my wildest dreams 20 years ago would have thought that we would be there. And I think that's part of the, you know, that sort of vision, that way of thinking about things I wonder and hope that at some point in the not too distant future, we'll be able to identify kids.Early at a window of opportunity for treatment line them up for the right safe treatment, if they needed and be able to bend that curve, put them on a different trajectory than they might otherwise have been on. Harry Glorikian: I've spent time you know, talking to Robert Green about BabySeq and sequencing, you know, children and, and you're right.I mean, if I think about from the day we were starting the genome project to now We we've revolutionized some areas. I mean, things that were a death sentence or whatever have completely changed. I'm not sure the public or people fully appreciate that. That's why, when somebody writes a paper, the genomic sequencing hasn't had an impact.I, it just drives me nuts. Okay we've talked about the benefits of all this, but if you could say to. Why should people donate their genetic data? I want to want to see if we can get some of the listeners to touch some of the people that they know or at least get the word out.And then what, what can the rest of us do to help? Sure. Wendy Chung: So, so if you'd like to participate, the website is sparkforautism.org, sparkforautism.org, right there on that website, on that landing page, you just, there's a tab that says join us today. And that starts you on the process of being able to sign up for doing this.You can share that with a friend. Everyone in the United States is welcome who has we call it a professional diagnosis of autism. So in other words, a psychologist a doctor you know someone has officially said that they have autism, not just that. They think it's a possibility, but someone has really said that they do have autism and of any age.So it could be a two year old to a 50 year old. And then as I said, their family members, so that's in terms of doing it in terms of, like I said, the information that you get back from it, I do hope. This, this, I will say also as a practicing geneticist, this doesn't replace me in terms of wearing my hat as a doctor providing genetic information.So if you're a pregnant mom out there who has a son with autism, and you're worried about, you know, the risks to your baby right now see a medical doctor about this because it takes us a little while on the research side, I won't be able to get you a result a week later, it does take time. So, so we're not meaning to replace the medical system.But as you're doing this, I do hope you'll find it helpful. Like I said, to get some of your own personal information genetically about autism, and most importantly, it's to be represented that is that I don't know where the insight is going to come from. And I want to make sure that we have information that's useful to us.Everyone across the spectrum, whether it be by age, whether it be by gender, whether it be by where you live in the United States, whether it be by your gene. There's so many different dimensions and it changes over the life course that it's a big ask. I realize. But we are committed to doing this and I will say it's through the generosity of the Simons family and the Simons Foundationthat we're committed to this for the long run. I don't have to worry about will NIH fund this for another five-year cycle. I don't have to worry about the upturn or the downturn of the economy or fundraising for this year. This is one of the truths in life that I can say this is going to be around for the longterm.And so you don't have to worry that this is going to disappear or go down in flames or that, you know, your samples and your information are going to be stuck in a freezer or warehouse. And no one's going to pay attention to this. This is, and I've emphasized this, but. This is what's driving autism research in the United States.There are literally hundreds of researchers that are using this as the way to know better. And if you want to be easily in touch with those researchers, find the cutting edge information. This is an easy way to become an insider. So I hope you'll use the opportunity in whatever way suits you best, but definitely share it with a friend and hopefully you'll be able to get something out of this too.Harry Glorikian: No, this is, this is fascinating. I'm, I'm really glad that we have the opportunity to talk and expose the listeners to this because I think what you're doing as a process needs to be replicated in a number of different areas. And then at some point it would be interesting to have a portal that would potentially share and aggregate that information in a, in a way But I, cause I always think, you know, we just don't know what we don't know yet and there's gotta be a way to evolve this as it goes forward.So it was great to talk to you. As I said, I feel like I know you from the PBS show, but great to actually meet you in person and look forward to publishing the episode and, and, you know, getting people excited about this opportunity.Wendy Chung: Well, thanks for having me and helping to increase the awareness and thanks for what you do educating the public about what science and big data are about is so incredible to educate all of us so that we can make better decisions.Harry Glorikian: Excellent. Thank you.Harry Glorikian: That's it for this week's show. You can find past episodes of MoneyBall Medicine at my website, glorikian.com, under the tab “Podcast.” And you can follow me on Twitter at hglorikian.  Thanks for listening, and we'll be back soon with our next interview.

SMA News Today's multimedia associate, Price Wooldridge, discusses Apitegromab being granted a fast track designation by the U.S. Food and Drug Administration. DeAnn Runge talks about her upcoming appointment with her neurologist to discuss continuing with Evrysdi or switching back to Spinraza. She dreads making the wrong decision. Are you interested in learning more about spinal muscular atrophy? If so, please visit https://smanewstoday.com/

One disease. Two families. Several different outcomes. Victoria Strong and Amy Medina share their experiences with Spinal Muscular Atrophy (SMA) Type 1 and how putting hope into action can change a disease forever.Links from today's episode:Read more of Victoria's story, learn about the Gwendolyn Strong Foundation, or shop Victoria's clothing brand at www.nevergiveup.org. Learn more about Amy Medina and her family at their CaringBridge site.Learn more about SMA here.

The mum of a Kent teenager with a rare disease says the decision to make a potentially life-extending drug available on the NHS is a dream come true. Mel Bolt from Minister has been campaigning for Spinraza to be made accessible to help her daughter Abbie, who has spinal muscular atrophy. The 15-year-old has battled with the incurable muscle-weakening condition since she was just two and is wheel-chair bound. https://www.kentonline.co.uk/